Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial.
Sarraju A, Li J, Cannon CP, Chang TI, Agarwal R, Bakris G, Charytan DM, de Zeeuw D, Greene T, Heerspink HJL, Levin A, Neal B, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Perkovic V, Jardine M, Mahaffey KW. Sarraju A, et al. Am Heart J. 2021 Mar;233:141-148. doi: 10.1016/j.ahj.2020.12.008. Epub 2020 Dec 22. Am Heart J. 2021. PMID: 33358942 Clinical Trial.
Assessing the Accuracy of an Online Chat-Based Artificial Intelligence Model in Providing Recommendations on Hypertension Management in Accordance With the 2017 American College of Cardiology/American Heart Association and 2018 European Society of Cardiology/European Society of Hypertension Guidelines.
Kassab J, El Dahdah J, Chedid El Helou M, Layoun H, Sarraju A, Laffin LJ, Cho L, Kapadia SR, Collier P, Harb SC. Kassab J, et al. Among authors: sarraju a. Hypertension. 2023 Jul;80(7):e125-e127. doi: 10.1161/HYPERTENSIONAHA.123.21183. Epub 2023 May 16. Hypertension. 2023. PMID: 37190998 No abstract available.
Canagliflozin and cardiovascular outcomes in Type 2 diabetes.
Sarraju A, Spencer-Bonilla G, Rodriguez F, Mahaffey KW. Sarraju A, et al. Future Cardiol. 2021 Jan;17(1):39-48. doi: 10.2217/fca-2020-0029. Epub 2020 Aug 4. Future Cardiol. 2021. PMID: 32748638 Free PMC article.
Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria.
Sarraju A, Bakris G, Cannon CP, Cherney D, Damaraju CV, Figtree GA, Gogate J, Greene T, Heerspink HJL, Januzzi JL Jr, Neal B, Jardine MJ, Blais J, Kosiborod M, Levin A, Lingvay I, Weir MR, Perkovic V, Mahaffey KW. Sarraju A, et al. J Am Coll Cardiol. 2022 Nov 1;80(18):1721-1731. doi: 10.1016/j.jacc.2022.08.772. J Am Coll Cardiol. 2022. PMID: 36302584 Free article. Clinical Trial.
64 results